These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 20607239)

  • 41. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
    Olmos D; Barker D; Sharma R; Brunetto AT; Yap TA; Taegtmeyer AB; Barriuso J; Medani H; Degenhardt YY; Allred AJ; Smith DA; Murray SC; Lampkin TA; Dar MM; Wilson R; de Bono JS; Blagden SP
    Clin Cancer Res; 2011 May; 17(10):3420-30. PubMed ID: 21459796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
    Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
    Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.
    Dent SF; Gelmon KA; Chi KN; Jonker DJ; Wainman N; Capier CA; Chen EX; Lyons JF; Seymour L
    Invest New Drugs; 2013 Dec; 31(6):1522-9. PubMed ID: 24072436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
    Schwartz GK; Carvajal RD; Midgley R; Rodig SJ; Stockman PK; Ataman O; Wilson D; Das S; Shapiro GI
    Invest New Drugs; 2013 Apr; 31(2):370-80. PubMed ID: 22661287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
    Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
    Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
    Tabernero J; Bahleda R; Dienstmann R; Infante JR; Mita A; Italiano A; Calvo E; Moreno V; Adamo B; Gazzah A; Zhong B; Platero SJ; Smit JW; Stuyckens K; Chatterjee-Kishore M; Rodon J; Peddareddigari V; Luo FR; Soria JC
    J Clin Oncol; 2015 Oct; 33(30):3401-8. PubMed ID: 26324363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Kelly KR; Shea TC; Goy A; Berdeja JG; Reeder CB; McDonagh KT; Zhou X; Danaee H; Liu H; Ecsedy JA; Niu H; Benaim E; Iyer SP
    Invest New Drugs; 2014 Jun; 32(3):489-99. PubMed ID: 24352795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
    Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL
    Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.
    Koyama T; Shimizu T; Iwasa S; Fujiwara Y; Kondo S; Kitano S; Yonemori K; Shimomura A; Iizumi S; Sasaki T; Furuse J; Yamamoto N
    Cancer Sci; 2020 Feb; 111(2):571-579. PubMed ID: 31797489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
    Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
    Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
    Honda K; Yamamoto N; Nokihara H; Tamura Y; Asahina H; Yamada Y; Suzuki S; Yamazaki N; Ogita Y; Tamura T
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):577-84. PubMed ID: 23860959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.
    Lewis NL; Lewis LD; Eder JP; Reddy NJ; Guo F; Pierce KJ; Olszanski AJ; Cohen RB
    J Clin Oncol; 2009 Nov; 27(31):5262-9. PubMed ID: 19738123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
    Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
    Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
    Huck JJ; Zhang M; McDonald A; Bowman D; Hoar KM; Stringer B; Ecsedy J; Manfredi MG; Hyer ML
    Mol Cancer Res; 2010 Mar; 8(3):373-84. PubMed ID: 20197380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
    Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
    Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
    Traynor AM; Hewitt M; Liu G; Flaherty KT; Clark J; Freedman SJ; Scott BB; Leighton AM; Watson PA; Zhao B; O'Dwyer PJ; Wilding G
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):305-14. PubMed ID: 20386909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
    Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
    Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
    Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
    Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.